BAJAJHCARE NSI Week ended 07 Aug 2026

Weekly Investor Report

Bajaj HealthCare Limited · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 329.8 INR
-2.0% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is 0.3% above the Trend Line and sits at 23.6% of its 52-week range. The latest completed week returned -2.0%, after a -5.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 57/100. Near-term considerations: volume confirmation is below normal.

Setup score 29 out of 100
Latest Close 329.8 INR 7 Aug 2026
1W Return -2.0% latest completed week
4W Return -5.4% short-term follow-through
12W Return 16.1% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -2.0% Latest completed week; four-week move -5.4%. Indicator stack 0/73 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 57/100 33 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 0.3% above the Trend Line and sits at 23.6% of its 52-week range. The latest completed week returned -2.0%, after a -5.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1512-week average 0.11

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.15Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -5.4% over four weeks, 16.1% over 12 weeks, and -26.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-2.0%
4W-5.4%
12W16.1%
26W-11.7%
52W-26.5%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.14Latest activity-pressure read.
Pressure change28.4%Four-week change in activity pressure.
Leadership-11.18Latest relative-leadership reading.
RS change-51.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 88%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength52/100Blend of value, momentum, and quality. Underlying universe rank 49; rank 1 is best.
Value64/100Relative valuation strength. Underlying universe rank 37; rank 1 is best.
Quality62/100Profitability and accounting quality. Underlying universe rank 39; rank 1 is best.
Momentum14/100Medium-term price momentum. Underlying universe rank 87; rank 1 is best.
Growth20/100Revenue and earnings growth. Underlying universe rank 81; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework41/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
70.1x
Price divided by trailing earnings.
Price / sales
1.8x
Market value relative to trailing revenue.
EV / EBITDA
17.5x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
1.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
45.5%
Gross profit retained from each unit of revenue.
Operating margin
10.0%
Operating profit retained from revenue.
Free-cash-flow margin
2.4%
Free cash flow generated from revenue.
Return on invested capital
6.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
12.6%
Latest one-year revenue growth.
EPS growth
-62.5%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
46.1%
Latest one-year free-cash-flow growth.
Piotroski F-score
7/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.3%
Cash dividends relative to market value.
Buyback yield
-4.7%
Net share repurchases relative to market value.
Shareholder yield
-4.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
2.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment57/100

Weighted news tone is neutral across 33 relevant articles.

2 positive · 29 neutral · 2 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-36.1%Distance below the 52-week high.
13-week volatility7.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+13.3%Week of 3 Jul.
Worst week-15.6%Week of 15 May.
Latest week-2.0%Week of 7 Aug.

Shape of recent returns

Strong gains7
Modest gains5
Flat weeks0
Modest losses8
Sharp losses6
Recent vol7.7%13-week weekly-return volatility.
Base vol5.8%52-week weekly-return volatility.
Up/down split23/29Count of positive and negative weeks in the 52-week window.
Average skew4.5% / -4.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape26/100

Trend, activity pressure, participation, and risk combine to a 26/100 tape read.

 Indicator analysis32/100

Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.15; No reversal markers Factors48/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 89; Small Cap Core rank 69 SVQF41/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 924.0 of 1576 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Sentiment57/100

Weighted news tone is neutral across 33 relevant articles.

Regeneron, Tenet leads top healthcare companies with highest earnings beats (XLV:NYSEARCA) Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 2026329.8 INR-2.0%328.7 INR412.7 INR1.14-11.18446.9KOff
31 Jul 2026336.5 INR4.1%330.9 INR412.7 INR1.36-9.271.3MOff
24 Jul 2026323.4 INR-13.5%333.6 INR413.0 INR1.39-11.124.7MOff
17 Jul 2026374.0 INR7.2%336.9 INR413.2 INR1.20-0.501.8MOff
10 Jul 2026348.7 INR1.2%338.3 INR412.9 INR0.88-7.371.1MOff
3 Jul 2026344.6 INR13.3%340.5 INR412.6 INR0.54-9.22153.2KOff
26 Jun 2026304.0 INR-2.8%343.0 INR412.5 INR0.25-19.630Off
19 Jun 2026313.0 INR3.0%347.3 INR412.5 INR0.21-17.89187.3KOff
12 Jun 2026303.8 INR3.5%351.0 INR412.5 INR0.16-19.77348.7KOff
5 Jun 2026293.5 INR-2.9%355.8 INR412.6 INR0.12-22.3866.2KOff
29 May 2026302.2 INR-1.1%360.8 INR412.5 INR0.33-21.48530.1KOff
22 May 2026305.5 INR7.5%366.6 INR412.4 INR0.38-22.00976.8KOff
15 May 2026284.1 INR-15.6%371.6 INR412.4 INR0.38-28.101.5MOff
8 May 2026336.5 INR4.6%377.8 INR412.6 INR0.47-17.681.3MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context